Disease · MONDO_0100096

COVID-19

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. COVID-19. Diseases, record MONDO_0100096. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100096

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: COVID-19; Open Targets
Open Targets ID: MONDO_0100096; Open Targets
Other names: 2019 novel coronavirus infection, 2019-nCoV infection, CoV-2 infection, coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2 infectious disease; Open Targets
Disease Ontology: DOID:0080600; Disease Ontology
MeSH: C000657245; MeSH
MeSH: D000086382; MeSH
Highest stage of its drugs: Approval, for 1 of its 540 drugs, from FDA; Open Targets

Drugs540

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
REMDESIVIR	CHEMBL4065616	Small molecule	Approval	FDA	67	66	66	Drugs and targets
HYDROXYCHLOROQUINE	CHEMBL1535	Small molecule	Phase 3	ClinicalTrials.gov	80	80	80	Drugs and targets
RITONAVIR	CHEMBL163	Small molecule	Phase 3	ClinicalTrials.gov	58	58	57	Drugs and targets
IVERMECTIN	CHEMBL6067487		Phase 3	ClinicalTrials.gov	55	55	55	Drugs and targets
NIRMATRELVIR	CHEMBL4802135	Small molecule	Phase 3	ClinicalTrials.gov	44	43	40	Drugs and targets
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 3	ClinicalTrials.gov	42	42	42	Drugs and targets
TOCILIZUMAB	CHEMBL1237022	Antibody	Phase 3	ClinicalTrials.gov	42	42	42	Drugs and targets
FAVIPIRAVIR	CHEMBL221722	Small molecule	Phase 3	ClinicalTrials.gov	38	38	38	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	30	30	25	Drugs and targets
COLCHICINE	CHEMBL107	Small molecule	Phase 3	ClinicalTrials.gov	27	27	27	Drugs and targets

1 to 10 of 540

See all 540 drugs

Targets337

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	16	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	9	Type-1 angiotensin II receptor antagonist	Phase 3	https://conductscience.org/library/genes/185	Drugs and targets
PTGS2	Cyclooxygenase	7	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Phase 3	https://conductscience.org/library/genes/5743	Drugs and targets
SERPINC1	Antithrombin-III	7	Antithrombin-III activator	Phase 3	https://conductscience.org/library/genes/462	Drugs and targets
ESR1	Estrogen receptor	6	Estrogen receptor agonist; Estrogen receptor alpha agonist; Estrogen receptor alpha modulator; Estrogen receptor modulator	Phase 2/3	https://conductscience.org/library/genes/2099	Drugs and targets
HRH1	Histamine H1 receptor	6	Histamine H1 receptor antagonist	Phase 3	https://conductscience.org/library/genes/3269	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	6	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Phase 3	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	6	Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator	Phase 3	https://conductscience.org/library/genes/3455	Drugs and targets
PTGS1	Cyclooxygenase	6	Cyclooxygenase inhibitor	Phase 3	https://conductscience.org/library/genes/5742	Drugs and targets
JAK2	Janus Kinase (JAK)	5	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Phase 3	https://conductscience.org/library/genes/3717	Drugs and targets

1 to 10 of 337

See all 337 targets

Trials1,093

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 61 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT07072793	A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe		131,005	2026-01-12	COVID-19 (Coronavirus Disease 2019)	NIRMATRELVIR, RITONAVIR	Its record names the disease	ClinicalTrials.gov
NCT04885530	ACTIV-6: COVID-19 Study of Repurposed Medications	Phase 3	10,956	2025-11-17	Covid19	FLUTICASONE FUROATE, FLUVOXAMINE, IVERMECTIN, METFORMIN, MONTELUKAST	Its record names the disease	ClinicalTrials.gov
NCT04425629	Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19	Phase 3	10,078	2023-12-21	COVID-19	CASIRIVIMAB, IMDEVIMAB	Its record names the disease	ClinicalTrials.gov
NCT04292899	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)	Phase 3	4,891	2020-12-31	COVID-19	REMDESIVIR	Its record names the disease	ClinicalTrials.gov
NCT04322682	Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)	Phase 3	4,506	2021-09-08	Corona Virus Infection	COLCHICINE	Its record names the disease	ClinicalTrials.gov
NCT04518410	ACTIV-2: A Study for Outpatients With COVID-19	Phase 2/3	4,044	2023-07-27	Coronavirus, Covid19	AMUBARVIMAB, BAMLANIVIMAB, CAMOSTAT, CASIRIVIMAB, CILGAVIMAB, CREXAVIBART, IMDEVIMAB, INTERFERON BETA-1A, OGALVIBART, ROMLUSEVIMAB, SAB-185, TIXAGEVIMAB	Its record names the disease	ClinicalTrials.gov
NCT05263908	A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19		3,346	2025-09-03	SARS-CoV-2 Infection	NIRMATRELVIR, RITONAVIR	Its record names the disease	ClinicalTrials.gov
NCT04427501	A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness	Phase 2/3	3,307	2022-03-07	COVID-19	BAMLANIVIMAB, BEBTELOVIMAB, ETESEVIMAB	Its record names the disease	ClinicalTrials.gov
NCT06042855	ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)	Phase 3	3,214	2025-07-20	Covid19	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT06291831	A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain.		3,011	2025-08-19	COVID-19	NIRMATRELVIR, RITONAVIR	Its record names the disease	ClinicalTrials.gov

1 to 10 of 1,093

See all 1,093 trials

Comparisons in its trials839

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Matched Treated: Long-term Disability vs Matched Untreated: Long-term Disability: Number of Participants With Any Long Term Disability (LTD) Claim: Matched Participants	50 of 20,318	74 of 20,318	40,636	NCT07072793	Trial comparisons
Matched Treated: Short-term Disability vs Matched Untreated: Short-term Disability: Number of Participants With Any Short Term Disability (STD) Claim: Matched Participants	1,343 of 20,065	1,848 of 20,065	40,130	NCT07072793	Trial comparisons
Colchicine vs Placebo: Number of Participants Who Required Mechanical Ventilation in the 30 Days Following Randomization.	11 of 2,235	21 of 2,253	4,488	NCT04322682	Trial comparisons
Colchicine vs Placebo: Number of Deaths in the 30 Days Following Randomization.	5 of 2,235	9 of 2,253	4,488	NCT04322682	Trial comparisons
Colchicine vs Placebo: Number of Participants Who Died or Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization.	104 of 2,235	131 of 2,253	4,488	NCT04322682	Trial comparisons
Colchicine vs Placebo: Number of Participants Who Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization.	101 of 2,235	128 of 2,253	4,488	NCT04322682	Trial comparisons
Colchicine vs Placebo: deaths from any cause	5 of 2,195	9 of 2,217	4,412	NCT04322682	Trial comparisons
Colchicine vs Placebo: serious adverse events	108 of 2,195	139 of 2,217	4,412	NCT04322682	Trial comparisons
Colchicine vs Placebo: Number of Participants Who Died or Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization in the Subgroup of Patients With PCR-confirmed COVID-19.	96 of 2,075	126 of 2,084	4,159	NCT04322682	Trial comparisons
Matched Treated: Absence Eligibility vs Matched Untreated: Absence Eligibility: Number of Participants With Presence of Any Absence Records: Matched Participants	1,255 of 1,909	1,331 of 1,909	3,818	NCT07072793	Trial comparisons

1 to 10 of 839

See all 839 comparisons in its trials

Papers from its trials980

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42053985	RESULT	1	PubMed
41754542	RESULT	1	PubMed
41429349	RESULT	1	PubMed
40886716	RESULT	1	PubMed
40383127	RESULT	1	PubMed
40360262	RESULT	1	PubMed
40261382	RESULT	1	PubMed
39770791	RESULT	1	PubMed
39601078	RESULT	2	PubMed
39459868	RESULT	1	PubMed

1 to 10 of 980

See all 980 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0100096

GET https://conductscience.org/api/diseases/v1/MONDO_0100096/drugs?page=2

API reference For AI assistants